HMMR and acute myeloid leukemia: Contrastingly, RHAMM has been critiqued for not meeting the ideal criteria as a target antigen in immunotherapy for AML, due to its expression in leukemic stem cells being comparable to that in healthy hematopoietic stem cells and its significant upregulation in proliferating cells and activated T cells [114].